Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

被引：10
|
作者：
Zinzani, Pier Luigi
Delwail, Vincent
Paneesha, Shankara
Rule, Simon
Garcia-Sancho, Alejandro Martin
Marin-Niebla, Ana
Salles, Gilles
Sancho, Juan-Manuel
Vergote, Vibeke
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Mehta, Amitkumar
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [31] Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/ Refractory Mantle Cell Lymphoma
    Gaitonde, Priyanka
    Cai, Ling
    de Miranda, Paulo
    Roos, Jack
    Rule, Simon
    Wang, Michael L.
    BLOOD, 2022, 140 : 3646 - 3647
  • [32] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre H.
    Casasnovas, Rene-Olivier
    Smith, Stephen D.
    Damaj, Gandhi Laurent
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Jain, Preetesh
    Brock, Graham
    Patel, Priti
    Tao, Lin
    Dlugosz-Danecka, Monika
    BLOOD, 2020, 136
  • [33] Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results From a Phase 2 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 6 - 7
  • [34] Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Guo, Haiyi
    Zhou, Lei
    Huang, Jane
    Novotny, William
    Kim, Pil
    Yu, Yiling
    Wu, Binghao
    Zhu, Jun
    BLOOD, 2022, 139 (21) : 3148 - 3158
  • [35] EFFECTIVENESS AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA TREATED IN ITALY ACCORDING TO THE IBRUTINIB NAMED PATIENT PROGRAM: THE REAL LIFE RESULTS
    Morigi, A.
    Sottotetti, F.
    Gotti, M.
    Spina, M.
    Volpetti, S.
    Ferrero, S.
    Spina, F.
    Pisani, F.
    Merli, M.
    Visco, C.
    Paolini, R.
    Zilioli, V. R.
    Baldini, L.
    Di Renzo, N.
    Tosi, P.
    Cascavilla, N.
    Molica, S.
    Ilariucci, F.
    Rigolin, G. M.
    D'Alo, F.
    Vanazzi, A.
    Santambrogio, E.
    Marasca, R.
    Mastrullo, L.
    Castellino, C.
    Desabbata, G.
    Scortechini, I.
    Trentin, L.
    Morello, L.
    Argnani, L.
    Zinzani, P. L.
    HAEMATOLOGICA, 2017, 102 : 49 - 50
  • [36] Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study
    Tam, Constantine S.
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Szafer-Glusman, Edith
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Wang, Michael
    BLOOD, 2020, 136
  • [37] A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
    Martin, Peter
    Bartlett, Nancy L.
    Blum, Kristie A.
    Park, Steven
    Maddocks, Kami
    Ruan, Jia
    Ridling, Leann
    Dittus, Christopher
    Chen, Zhengming
    Huang, Xiangao
    Inghirami, Giorgio
    DiLiberto, Maurizio
    Chen-Kiang, Selina
    Leonard, John P.
    BLOOD, 2019, 133 (11) : 1201 - 1204
  • [38] Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
    Portell, Craig A.
    Wages, Nolan A.
    Kahl, Brad S.
    Budde, Lihua E.
    Chen, Robert W.
    Cohen, Jonathon B.
    Varhegyi, Nikole E.
    Petroni, Gina R.
    Williams, Michael E.
    BLOOD ADVANCES, 2022, 6 (05) : 1490 - 1498
  • [39] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Miljkovic, Milos D.
    Phelan, James D.
    Muppidi, Jagan R.
    Thomas, Craig J.
    Ceribelli, Michele
    Juanitez, Anna Marie
    Pradhan, Amynah
    Hillsman, Amy
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2021, 138
  • [40] A phase 2 study of the PI3K5 inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
    Phillips, Tycel J.
    Avigdor, Abraham
    Gurion, Ronit
    Patti, Caterina
    Corradini, Paolo
    Tani, Monica
    Mehta, Amitkumar
    Lossos, Izidore S.
    Zinzani, Pier Luigi
    Thieblemont, Catherine
    Jurczak, Wojciech
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Jiang, Ping
    Johnson, Peter
    BLOOD ADVANCES, 2024, 8 (04) : 867 - 877
12345